Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases

Arthritis and Rheumatism

Volumn 65, Issue 1, 2013, Pages 48-58

  Haynes, Kevin ^a   Beukelman, Timothy ^b   Curtis, Jeffrey R ^b   Newcomb, Craig ^a   Herrinton, Lisa J ^c   Graham, David J ^d   Solomon, Daniel H ^e   Griffin, Marie R ^f   Chen, Lang ^b   Liu, Liyan ^c   Saag, Kenneth G ^b   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c KAISER PERMANENTE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; RETINOID DERIVATIVE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ALGORITHM; ANKYLOSING SPONDYLITIS; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; ENTERITIS; FEMALE; HUMAN; IMMUNOPATHOLOGY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; SOLID TUMOR; STEROID THERAPY; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOLOGIC FACTORS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871745363     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37740     Document Type: Article

References (38)

1. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L,. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180-1.
2. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
3. Zintzaras E, Voulgarelis M, Moutsopoulos HM,. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-44.
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295:2482]. JAMA 2006; 295: 2275-85.
5. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ,. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009; 68: 1177-83.
6. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
7. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D,. Cancer risk with tumor necrosis factor α (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-30.
8. Thompson AE, Rieder SW, Pope JE,. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011; 63: 1479-85.
9. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, et al. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf 2011; 20: 1199-209.
10. Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S,. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 2007; 18: 561-9.
11. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al, on behalf of the Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 1263-71.
12. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-18.
13. Glynn RJ, Schneeweiss S, Sturmer T,. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253-9.
14. Lin DY, Wei LJ,. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074-8.
15. Lewis JD,. Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease. Gut 2010; 59: 1586-7.
16. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
17. Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95.
18. Wolfe F, Michaud K,. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-9.
19. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20.
20. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6.
21. Chakravarty EF, Michaud K, Wolfe F,. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-5.
22. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180-9.
23. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL,. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 1080-7.
24. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
25. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD,. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5.
26. Singh H, Nugent Z, Demers AA, Bernstein CN,. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141: 1612-20.
27. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al, for the CESAME Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8.e5.
28. Fraumeni JF Jr, Curtis RE, Edwards BK, Tucker MA,. Introduction. In:, Curtis RE, Freedman DM, Ron E, Ries LA, Hacker DG, Edwards BK, et al, editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. NIH Publication No.: 05-5302. Bethesda, MD: National Cancer Institute; 2006. p. 1-7.
29. Lewis JD, Schwartz JS, Lichtenstein GR,. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-24.
30. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133: 769-79.
31. Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005; 53: 872-8.
32. Buch MH, Bingham SJ, Bryer D, Emery P,. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 2007; 46: 1153-6.
33. Ogale S, Hitraya E, Henk HJ,. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011; 12: 204.
34. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
35. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
36. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD,. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.
37. Long MD, Kappelman MD, Pipkin CA,. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis 2011; 17: 1423-7.
38. Hutfless S, Fireman B, Kane S, Herrinton LJ,. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 598-605.